Introducing The Journal: Trillion Dollar Shot

Protein is everywhere — tons of us are trying to cram more of it into our diets, and it's showing up in our lattes, our snack bars, even our popcorn. But just as we’re getting on board with protein-maxxing, a bunch of headlines have started saying the opposite: that eating LESS p ...  Show more

Sunscreen is supposed to protect us from dangerous stuff like cancer, but all over social media, people are saying that we’ve been getting it all wrong. We’re being told that our sunscreen is full of toxic chemicals, that wearing it could mess with our vitamin D levels — even tha ...  Show more

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo No ...  Show more

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ...  Show more

First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ...  Show more

Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?

Links: